FABP4 and gastrointestinal stromal tumor: The multivariate analysis suggested that poor prognosis in patients with GIST was significantly associated with high‐FABP4 expression (p = 0.021) and high AFIP‐Miettinen risk (p < 0.001) (Table 2).